Search results for Evolocumab

Evolocumab Biosimilar – Anti-PCSK9 mAb – Research Grade, ProteoGenix, PX-TA1307

Description of Evolocumab Biosimilar - Anti-PCSK9 mAb - Research Grade General information on Anti-PCSK9[Homo sapiens] (Evolocumab) Monoclonal Antibody Evolocumab is a human IgG2 monoclonal antibody that binds to and prevents the binding of the proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that binds to LDL receptors for degradation, thus reducing the liver’s activity of removal of LDL-cholesterol (LDL-C) from the blood. It is used in the treatment of hyperlipidemia.

Evolocumab, Kyinno, KB-1073

Evolocumab, Affinityimmuno, ab-131-evolocumab

Evolocumab, Abbexa, abx831265

Evolocumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PCSK9, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9).

Evolocumab ELISA Kit, ProteoGenix, KPTX395

Description of Evolocumab ELISA Kit Evolocumab ELISA Kit: A Comprehensive Guide Introduction Evolocumab is a monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein involved in regulating the levels of low-density lipoprotein (LDL) cholesterol in the blood. High levels of LDL cholesterol have been linked to an increased risk of cardiovascular diseases, making PCSK9 an attractive therapeutic target. The Evolocumab ELISA Kit is a valuable tool for researchers studying the mechanism of action and potential applications of this novel drug. Structure of Evolocumab Evolocumab is a fully human monoclonal antibody, meaning it is derived from human cells and has a high affinity for its target protein. It consists of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 25 kDa. The antibody has a Y-shaped structure, with two antigen binding sites at the tips of the Y, allowing it to bind to two PCSK9 molecules simultaneously. Activity of Evolocumab The primary mechanism of action of Evolocumab is inhibition of PCSK9. This protein binds to the LDL receptor (LDLR) on the surface of liver cells and promotes its degradation, leading to increased levels of LDL cholesterol in the blood. Evolocumab binds to PCSK9 and prevents it from interacting with LDLR, allowing the receptor to remain on the cell surface and continue removing LDL cholesterol from the blood. In addition to its LDL-lowering effects, Evolocumab has been shown to increase the number of LDLR on the surface of liver cells, further enhancing its ability to reduce LDL cholesterol levels. This effect is thought to be due to the inhibition of PCSK9-mediated degradation of LDLR. Applications of Evolocumab ELISA Kit Therapeutic Target The Evolocumab ELISA Kit is a valuable tool for researchers studying the potential therapeutic applications of this drug. The kit allows for the accurate and sensitive quantification of Evolocumab levels in various biological samples, such as serum or plasma. This information can help researchers understand the pharmacokinetics and pharmacodynamics of the drug, as well as its potential efficacy and safety. Furthermore, the Evolocumab ELISA Kit can be used to measure the levels of PCSK9 in biological samples, providing insights into the mechanism of action of Evolocumab and its effects on PCSK9 levels. This information can help identify potential biomarkers for monitoring the response to treatment and predicting patient outcomes. Research Use In addition to its therapeutic potential, Evolocumab has also been studied for its role in research. The Evolocumab ELISA Kit can be used to measure the levels of Evolocumab in animal models, allowing researchers to assess its pharmacokinetics and pharmacodynamics in preclinical studies. This information can help guide the development of new therapies targeting PCSK9 and other related proteins. Furthermore, the Evolocumab ELISA Kit can also be used to measure the levels of PCSK9 in various disease states, such as hypercholesterolemia and cardiovascular diseases. This can provide valuable insights into the role of PCSK9 in these conditions and the potential for Evolocumab as a therapeutic agent. Conclusion In summary, the Evolocumab ELISA Kit is a powerful tool for researchers studying the structure, activity, and potential applications of this novel drug. Its ability to accurately measure Evolocumab and PCSK9 levels in various biological samples makes it an essential tool for understanding the mechanism of action of Evolocumab and its potential as a therapeutic agent. Furthermore, the kit can also be used for research purposes, providing valuable insights into the role of PCSK9 in various disease states.

Anti-Evolocumab Polyclonal Antibody, AntibodySystem, PAJ24001

Evolocumab Biosimilar - Research Grade, ichor.bio, ICH4023

Detects human PCSK9. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Evolocumab.

Research Grade Evolocumab (HV275026), abinScience, HV275026

Anti-Evolocumab Neutralizing Antibody (SAA2613), ProteoGenix, PTX27117